Pharmalink

Pharmalink, a Swedish pharmaceutical company which makes orphan and niche products, has appointed three new members to its Board of Directors. Ann-Tove Kongsnes (pictured), Hilde Furberg and Olav Hellebø were elected at a recent shareholders’ meeting in Stockholm, at which Elisabeth Lindner stepped down from the Board.

Kongsnes is an Investment Director at Investinor, Norway’s largest investor in venture and expansion capital and an investor in Pharmalink.

Furberg has worked for 30 years in the pharmaceutical industry. She is currently Senior VP for Rare Disease (Europe, the Middle East and Africa) at Genzyme, which she joined in 2002. She opened the Genzyme’s first operation in the Nordic region and has also held responsibility for the company in the Benelux region. Prior to Genzyme, Furberg spent 15 years at Baxter, before which she was involved in the founding of Pharmalink.  

Hellebø is the chairman and co-founder of Palma Biotech S.L. in Spain, and has previously served as CEO of Clavis Pharma ASA and Senior VP at UCB Pharma.